1.31
+0.035(+2.76%)
Currency In USD
Address
80 West Lancaster Avenue
Devon, PA 19333
United States of America
Phone
484 581 7505
Website
Sector
Healthcare
Industry
Medical - Pharmaceuticals
Employees
25
First IPO Date
January 29, 2018
| Name | Title | Pay | Year Born |
| James E. Fickenscher | Chief Financial Officer & Vice President of Corporation Devel. (Leave of Absence) | 607,622 | 1964 |
| Kenneth T. Jones | Vice President, Corporation Controller & Interim Chief Financial Officer | 0 | 1964 |
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania.
